Ovarian cancer

van der Burg, 1995, The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynaecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer, N. Engl. J. Med., 332, 629, 10.1056/NEJM199503093321002

Kuhn, 2001, Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma, Cancer, 92, 2585, 10.1002/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#

Junor, 1999, Specialist gynaecologists and survival outcome in ovarian cancer, Br. J. Obstet. Gynaecol., 106, 1130, 10.1111/j.1471-0528.1999.tb08137.x

McGuire, 1964, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101

Piccart, 2000, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer, J. Natl. Cancer Inst., 92, 699, 10.1093/jnci/92.9.699

Neijt, 2000, Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J. Clin. Oncol., 18, 3084, 10.1200/JCO.2000.18.17.3084

Kaye, 2001, The integration of docetaxel into first-line chemotherapy for ovarian cancer, Int. J. Gynecol. Cancer, 11, 31, 10.1046/j.1525-1438.2001.11(suppl.1)sup1031.x

Vasey, 2001, Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer, Br. J. Cancer, 84, 170, 10.1054/bjoc.2000.1572

Vasey, 2001, Preliminary results of the SCOTROC trial, Proc. ASCO, 20, 202a

Markman, 2001, Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum, J. Clin. Oncol., 19, 1901, 10.1200/JCO.2001.19.7.1901

du Bois, 1999, First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer, J. Clin. Oncol., 17, 46, 10.1200/JCO.1999.17.1.46

Luck, 2001, The integration of anthracyclines in the treatment of advanced ovarian cancer, Int. J. Gynecol. Cancer, 11, 34, 10.1046/j.1525-1438.11.s1.2.x

Hansen, 2002, Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma, Semin. Oncol., 29, 17, 10.1053/sonc.2002.31593

Muggia, 2000, Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer, J. Clin. Oncol., 18, 106, 10.1200/JCO.2000.18.1.106

Colombo, 2000, Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin, Proc. ASCO, 19, 379a

Cassinelli, 2001, A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes, Int. J. Cancer, 92, 738, 10.1002/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2

Wagner, 2001, Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125, Clin. Cancer Res., 7, 1154

Alberts, 1996, Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N. Engl. J. Med., 335, 1950, 10.1056/NEJM199612263352603

Nicholson, 2000, A randomized phase III trial of adjuvant intraperitoneal radioimmuno-therapy in ovarian cancer, Proc. ASCO, 19, 383a

du Bois, 2001, Treatment of advanced ovarian cancer, Eur. J. Cancer, 37, S1, 10.1016/S0959-8049(01)00328-8

Harries, 2001, Recent advances in the treatment of epithelial ovarian cancer, Expert. Opin. Investig. Drugs, 10, 1715, 10.1517/13543784.10.9.1715

Rose, 1998, Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma, J. Clin. Oncol., 16, 405, 10.1200/JCO.1998.16.2.405

ten Bokkel Huinink, 1997, Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer, J. Clin. Oncol., 15, 2183, 10.1200/JCO.1997.15.6.2183

Bookman, 1998, Topotecan for the treatment of advanced epithelial ovarian cancer, J. Clin. Oncol., 16, 3345, 10.1200/JCO.1998.16.10.3345

Johnston, 2001, Caelyx, Eur. J. Cancer, 37, S8, 10.1016/S0959-8049(01)00329-X

Vermorken, 2000, A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group, Ann. Oncol., 11, 1035, 10.1023/A:1008332517333

Friedlander, 1998, A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer, Ann. Oncol., 9, 1343, 10.1023/A:1008469212268

Lund, 1995, Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients, Anticancer Drugs, 6, 61, 10.1097/00001813-199512006-00010

von Minckwitz, 1999, Phase II study of gemcitabine in ovarian cancer, Ann. Oncol., 10, 853, 10.1023/A:1008364327684

Sorensen, 2001, Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma, Gynecol. Oncol., 81, 58, 10.1006/gyno.2000.6089

Bajetta, 1996, Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer, J. Clin. Oncol., 14, 2546, 10.1200/JCO.1996.14.9.2546

Piccart, 2000, Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer, J. Clin. Oncol., 18, 1193, 10.1200/JCO.2000.18.6.1193

Plaxe, 2002, Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer, Am. J. Clin. Oncol., 25, 45, 10.1097/00000421-200202000-00009

Plaxe, 2002, Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer, Gynecol. Oncol., 84, 32, 10.1006/gyno.2001.6441

Kehrer, 2002, Phase I and pharmacologic study of liposomal lurtotecan, NX 211, J. Clin. Oncol., 20, 1222, 10.1200/JCO.20.5.1222

Kelland, 1999, Mini-review, J. Inorg. Biochem., 77, 111, 10.1016/S0162-0134(99)00141-5

Vasey, 2000, Phase II trial of capecitabine in relapsed ovarian cancer, Ann. Oncol., 11, 84

Bradley, 2001, Tumor targeting by conjugation of DHA to paclitaxel, J. Control Release, 74, 233, 10.1016/S0168-3659(01)00321-2

Hidalgo, 2001, Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J. Clin. Oncol., 19, 2493, 10.1200/JCO.2001.19.9.2493

Finkler, 2001, Phase II evaluation of OSI-774, a potent oral antagonist of EGFR-TK in patients with advanced ovarian cancer, Proc. ASCO., 20, 208a

Fracasso, 2001, Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma, J. Clin. Oncol., 19, 2975, 10.1200/JCO.2001.19.12.2975

Vasey, 2002, Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer, J. Clin. Oncol., 20, 1562, 10.1200/JCO.20.6.1562